|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 325 7TH STREET, NW, #1200 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31326-12
|
||||||||
|
6. House ID# 313540000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anthony J. Principi |
Date | 04/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Global intellectual property rights protection (no bills)
International pharmaceutical market access (no bills)
WTO accession and implementation issues (no bills)
HR 4279 (Pro-IP Act)
US-Korea Free Trade Agreement (no bills)
US-Peru Free Trade Agreement (no bills)
US-Columbia Free Trade Agreement (no bills)
US-Panama Free Trade Agreement (no bills)
Norway Patent issues (no bills)
Poland market access (no bills)
Russia permanent normal trade relations (no bills)
Turkey Market Access (no bills)
Free Trade Agreement Implementation Legislation (Peru, Columbia, Panama, Korea, Israel, Saudi Arabia)
OECD Accession
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), State - Dept of (DOS), Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joseph |
Damond |
|
|
|
Stephanie |
Henning |
|
|
|
Lisa |
Coen |
|
|
|
Anthony |
Principi |
|
|
|
Kimberly |
Pinter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Veterans Healthcare issues
Electronic Prescribing
Comparative Effectiveness Research
S. 2408, Medicare Electronic Medication and Safety Protection Act 2007
HR. 4296, Medicare Electronic Medication and Safety Protection Act 12/07
HR. 3800, Promoting Health Information Technology Act 10/07
HR. 2406, (no title) authorize the NIST to increase its efforts in support of the integration of the healthcare information enterprise in the United States 11/07
S. 1693, The Wired for Health Care Quality Act 10/07
S. 438, Fair Prescription Drug Competition Act 1/07
S. 1082, Food and Drug Administration Revitalization Act 5/07
HR. 806 2/07
S. 358, Genetic Information Nondiscrimination Act 4/07
S. 1432, Preserve Access to Affordable Generics Act 5/07
S. 316, Preserve Access to Affordable Generics Act 3/07
S. 2029 Physician Payments Sunshine Act
HR 5605 Physician Payments Sunshine Act
HR 962 Preservation of Antibioties for Medical Treatment Act
S. 349 Preservation of Antibioties for Medical Treatment Act
S. 2313 Strategies to Address Antimicrobial Resistance
HR 3697 Strategies to Address Antimicrobial Resistance
HR 1424. The Paul Wellstone Mental Health and Addiction Equity Act
S 2731, The Tom Lantos and Henry J. Hyde United States Global Leadership Against HIVAIDS, Tuberculosis, and Malaria Reauthorization Act (Also HR 5501)
E-Meds Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Carey |
|
|
|
Dolly |
Judge |
|
|
|
Anthony |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
|
Lisa |
Coen |
|
|
|
Myron |
Terry |
|
|
|
Anne |
Wilson |
|
|
|
Vera |
Grill |
|
|
|
John |
Halliwell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Animal Drug User Fee Act Reauthorization - no bill yet.
HR. 3161, Agriculture Appropriations, pharmaceutical counterfeiting, importation - 08
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dolly |
Judge |
|
|
|
Louis A. |
LaMarca |
|
|
|
Anthony J. |
Principi |
|
|
|
Chris |
Carey |
|
|
|
John |
Halliwell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H. Con. Res 312 -Medicare and Medicaid, Budget Reconciliation, pharmaceutical counterfeiting, importation, AIDS Drug Assistance
Programs Supplemental FY 08 BR
S. Con Res 70 - Budget Reconciliation, pharmaceutical counterfeiting, importation FY 08
HR 3610 Food & Drug Import Safety Act
HR. 2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006,
pharmaceutical counterfeiting, importation FY 07
S. Con Res. 18, budget reconciliaton, pharmaceutical counterfeiting, importation 3/07
S. Con Res. 21, budget resolution, non-interference 5/07
HR. 3043, Department of Labor, Health and Human Services, and Education, and related Agencies Appropriation Act FY 2008, Pharmaceutical counterfeiting, Importation
HR. 3161, FY 2008 Agriculture Appropriations Bill (importation)
S. 1710, Labor/HHS Appropriations 6/07
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anthony J. |
Principi |
|
|
|
Dolly |
Judge |
|
|
|
Louis A. |
LaMarca |
|
|
|
John |
Halliwell |
|
|
|
Chris |
Carey |
|
|
|
Anne |
Wilson |
|
|
|
Myron |
Terry |
|
|
|
Vera |
Grill |
|
|
|
Joe |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
HR. 1432, Preserve Access to Affordable Generics Act (settlements) 3/07
S. 316, Preserve Access to Affordable Generics Act (settlements) 3/07
S. 445, Patent Reform Act
HR 1908, Patent Reform Act
S 2300, Lower PRICED Drugs Act, legislation pediatric exclusivity, citizens petitions
HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions
S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics
HR 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs
HR 5120, To Amend Title 35, United States Code, to confirm certain filing provisions within the Patent and Trademark Office.
HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges
S 438, Fair Prescription Drug Competition Act (ban authorized generics) 1/07
HR 780, Counterfeit Drug Prevention Act of 2007 3/07
HR 1908, Patent Reform Act of 2007
S 1145, Patent Reform Act of 2007
S 623, Access to Life-Saving Medication Act (FOBS) 2/07
HR 1038, Access to Life-Saving Medication Act
HR 5629, Pathway For Biosimilars Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dolly |
Judge |
|
|
|
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
|
Myron |
Terry |
|
|
|
Chris |
Carey |
|
|
|
Lisa |
Coen |
|
|
|
Joe |
Damond |
|
|
|
Stephanie |
Henning |
|
|
|
John |
Halliwell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting
S 2699, Neglected Diseases Elimination Act, promote R&D
S 484, Enhancing Drug Safety and Innovation Act 2006
S 1082, FDA Revitalization Act 3/07
HR 2900, FDA Amendments Act 2007
S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07
HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dolly |
Judge |
|
|
|
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
|
Myron |
Terry |
|
|
|
John |
Halliwell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 4, Medicare Prescription Drug Price Negotiation Act of 2007
S 3, Medicare Prescription Drug Price Negotiation Act of 2007
HR 1014 - Paul Wellstone Mental Health & Addiction Equity Act of 2007- Medicaid
HR 3963 - Childrens Health Insurance Program Extension & Improvement
S 558 - Paul Wellstone Mental Health & Addiction Equity Act of 2007- Medicaid
HR 1424, Paul Wellstone Mental Health & Addiction Equity Act of 2007- Medicaid
Medicare prescription drug benefit implementation (no bills) - retain
Medicaid rebates (no bills) - retain the general issues section
Medicaid coverage (no bills)
Average Manufacturer Price Regulation
HR. 3162, Childrens Health and Medicare Protection Act 2007
HR. 976/2963, Childrens Health Insurance Program Reauthorization 2007
HR. 118, To amend part D of title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negotiate prices for part D covered drugs for Medicare beneficiaries 2/07
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Carey |
|
|
|
Dolly |
Judge |
|
|
|
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
|
Myron |
Terry |
|
|
|
Anne |
Wilson |
|
|
|
Vera |
Grill |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
HR 2850, Green Chemistry Research and Development Act of 2007, environmental conservation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
S. 1547, National Defense Authorization Act for FY 2009
HR. 1585, National Defense Authorization Act for FY 2009
S. 1547, Defense Authorization Act of FY 2009
HR. 1585, Defense Authorization Act of FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vera |
Grill |
|
|
|
Chris |
Carey |
|
|
|
Anne |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR. 2138, R&D tax credit extension 5/07
S. 41, R&D tax credit extension 1/07
S. 41, S. 2209, HR. 1712, R&E tax credit 2007 - all three
Tax treaties with Belgium, Denmark, Finland and Germany
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Pinter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
SCI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |